What is new in HIV/AIDS research in developing countries?

Tropical Medicine and International Health

Volumn 15, Issue 8, 2010, Pages 975-980

  Kamali, Anatoli ^a  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

developing countries; HIV; research

Indexed keywords

ACICLOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; DAPIVIRINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ERDOSTEINE; FLUCONAZOLE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MARAVIROC; TENOFOVIR; TENOFOVIR DISOPROXIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING WORLD; DISEASE PREVALENCE; DISEASE TRANSMISSION; EPIDEMIC; HEALTH POLICY; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CIRCUMCISION; CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG MONITORING; GENITAL ULCER; HEALTH BEHAVIOR; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE HOMOSEXUAL; MEDICAL RESEARCH; NONHUMAN; OPPORTUNISTIC INFECTION; REVIEW; VIRUS TRANSMISSION;

AIDS VACCINES; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; BIOMEDICAL RESEARCH; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS;

SUB-SAHARAN AFRICA;

HUMAN HERPESVIRUS 2;

EID: 77954717746     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2010.02566.x     Document Type: Review

References (41)

1. Apondi R, Bunnell R, Awor A et al. (2007) Home-based antiretroviral care is associated with positive social outcomes in a prospective cohort in Uganda. Journal of Acquired Immune Deficiency Syndromes 44, 71 76.
2. Auvert B, Taljaard D, Lagarde E et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Medicine 2, e298.
3. Baggaley RF, Garnett GP Ferguson NM (2006) Modelling the impact of antiretroviral use in resource-poor settings. PLoS Medicine 3, e124.
4. Bailey RC, Moses S, Parker CB et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369, 643 656.
5. Bakobaki JM, Lacey CJ, Bukenya M et al. (2005) A randomized controlled safety and acceptability trial of DS gel in sexually active women in Uganda. AIDS 19, 2149 2156.
6. Bentley ME, Fullem AM, Tolley EE et al. (2004) Acceptability of a Microbicide among women and their partners in a 4-Country phase I trial. American Journal of Public Health 94, 1159 1164.
7. Buchbinder SP, Mehrotra DV, Duerr A et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881 1893.
8. Castilla J, Del Romero J, Hernando V, Marincovich B, García S Rodríguez C (2005) Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. Journal of Acquired Immune Deficiency Syndromes 40, 96 101.
9. Cates W Feldblum P (2008) HIV prevention research: the ecstasy and the agony. Lancet 372, 932 933.
10. Celum C, Wald A, Hughes J et al. (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371, 2109 2119.
11. Celum C, Wald A, Lingappa JR et al. (2010) Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. New England Journal of Medicine 362, 427 439.
12. Chisembele M, Crook A, Gafos M et al. (2010) PRO2000 Vaginal Gel is Ineffective in Preventing HIV Infection: Results of the MDP301 Phase III Microbicide Trial. CROI Abstract #87LB.
13. DART Trial (2010) Team Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial. Lancet 375, 123 131.
14. Granich RM, Gilks CF, Dye C, De Cock KM Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373, 48 57.
15. Gray RH, Kigozi G, Serwadda D et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369, 657 666.
16. Grosskurth H, Mosha F, Todd J et al. (1995) Impact of improved treatment of sexually transmitted diseases on HIV-1 infection in rural Tanzania: randomised controlled trial. Lancet 346, 530 536.
17. Guay LA, Musoke P, Fleming T et al. (1999) Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354, 795 802.
18. Jaffar S, Amuron B, Foster S et al. (2009) Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet 374, 2080 2089.
19. Karim SA, Coletti A, Richardson B et al. (2009) Safety and Effectiveness of Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel for the Prevention of HIV Infection in Women: Results of the HPTN 035 Trial. CROI, Abstract #48LB.
20. Klasse PJ, Shattock R Moore JP (2008) Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annual Review of Medicine 59, 291 307.
21. McCormack S, Hayes R, Lacey CJN Johnson AM (2001) Science, medicine and the future: microbicides in HIV prevention. British Medical Journal 322, 410 413.
22. Parkes-Ratanshi R, Kamali A, Wakeham K et al. (2009) Successful Primary Prevention of Cryptococcal Disease Using Fluconazole Prophylaxis in HIV-infected Ugandan Adults. CROI Abstract #32.
23. Pinkerton SD (2008) Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS and Behavior 12, 677 684.
24. Ramjee G, Gouws E, Andrews A et al. (2001) The acceptability of a vaginal microbicide among South African men. International Family Planning Perspectives 27, 164 170.
25. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. (2009) Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. New England Journal of Medicine 361, 2209 2220.
26. Shafer LA, Biraro S, Nakiyingi-Miiro J et al. (2008) HIV prevalence and incidence are no longer falling in southwest Uganda: evidence from a rural population cohort 1989-2005. AIDS 22, 1641 1649.
27. Shaffer N, Chuachoowong R, Mock PA et al. (1999) Short-course zidovudine for perinatal HIV-1 ransmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 353, 773 780.
28. Smith SM (2004) Pre-exposure chemoprophylaxis for HIV: it is time. Retrovirology 1, 16.
29. Smith DK, Grohskopf LA, Black RJ et al. (2005) Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. Morbidity and Mortality Weekly Report 54, 1 20.
30. Subbarao S, Otten RA, Ramos A et al. (2006) Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. Journal of Infectious Diseases 194, 904 911.
31. Tsai CC, Follis KE, Sabo A et al. (1995) Prevention of SIV infection in macaquesby (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 270, 1197 1199.
32. UNAIDS (2009) AIDS Epidemic Update. UNAIDS
33. Vernazza PL, Bruce GL, Dyer J et al. (1997) Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 11, 987 993.
34. Wawer JM, Makumbi, F, Kigozi G et al. (2009) Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 374, 229 237.
35. Walker LM, Phogat SK, Chan-Hui P et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine. Science 326, 285 326.
36. Watson-Jones D, Weiss HA, Rusizoka M et al. (2008) Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. New England Journal of Medicine 358, 1560 1571.
37. WHO/UNAIDS (2005) Update Report. http://www.who.int/3by5.
38. Wiktor SZ, Ekpini E, Karon JM et al. (1999) Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abdijan, Cote d'Ivoire: a randomised trial. Lancet 353, 781 785.
39. Youle M Wainberg MA (2003) Could chemoprophlaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS 17, 937 938.
40. Zachariah R, Harries AD, Luo C, Bachman G Graham SM (2007) Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries. The Lancet Infectious Diseases 7, 686 693.
41. Zhang H, Dornadula G, Beumont M et al. (1998) Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. New England Journal of Medicine 339, 1803 1809.